Genmab A/S (GMAB)

Healthcare · Biotechnology · NASDAQ

Genmab A/S (GMAB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $19.49B, a trailing price-to-earnings ratio of 21.1 and a free-cash-flow yield of 5.8%. Over the most recent reported fiscal year, revenue grew 19.2% and free cash flow per share grew 7.8%.

Market cap	$19.49B
Trailing P/E	21.1
FCF yield	5.8%
Revenue growth (YoY)	+19.2%
EPS growth (YoY)	-1.7%
FCF/share growth (YoY)	+7.8%
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

Explore live GMAB data on Nama Insights →

Recent Congressional trades

Genmab A/S trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Buy	$1,001 - $15,000	Feb 6, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 12, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 8, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 8, 2023
Thomas R Carper	Senate	Buy	$1,001 - $15,000	—